14
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Type 2-high asthma is associated with a specific indoor mycobiome and microbiome

      research-article
      , PhD 1 , 2 , 3 , , , MD 1 , 2 , 4 , , PhD 3 , , MD 4 , , MD, PhD 1 , 2 , 4 , , PhD 3 , , MD, PhD 1 , 2 , 4 , , MD, PhD 1 , 2 , 4 ,
      The Journal of Allergy and Clinical Immunology
      Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.
      Indoor environment, mycobiome, microbiome, severe asthma, FeNO, Type 2 asthma, BMI, Body mass index, BAL, Bronchoalveolar lavage, COBRA, Cohort of Bronchial obstruction and Asthma, EDC, Electrostatic Dust Collector, ERS, European Respiratory Society, EXA, Exacerbation of asthma, FeNO, Fraction of exhaled nitric oxide, ICS, Inhaled corticosteroid, IL, Interleukin, ITS2, Internal transcribed spacer 2, LABA, Long acting beta2 agonist, LDA, Linear discriminant analysis, LAMA, Long acting muscarinic antagonist, NGS, Next generation sequencing, OCS, Oral corticosteroid, OTU, Operational taxonomic unit, PCoA, principal coordinates analysis, PERMANOVA, Permutational multivariate analysis of variance, qPCR, Quantitative polymerase chain reaction, SA, Severe asthma, STB, Stable state, T2, Type 2, VRC, Voriconazole, V3-V4, Variable 3-variable 4 of the 16S rRNA encoding gene

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The links between microbial environmental exposures and asthma are well documented, but no study has combined deep-sequencing results from pulmonary and indoor microbiomes of asthmatic patients with spirometry, clinical and endotype parameters.

          Objective

          The goal of this study was to investigate the links between indoor microbial exposures and pulmonary microbial communities and to document the role of microbial exposures on inflammatory and clinical outcomes of patients with severe asthma (SA).

          Methods

          Fifty-five SA patients from the national COBRA cohort were enrolled for analyzing their indoor microbial flora through the use of electrostatic dust collectors (EDCs). Among these patients, 22 were able to produce sputa during stable or pulmonary exacerbation periods and had complete pairs of EDC and sputum samples, both collected and analysed. We used amplicon targeted metagenomics to compare microbial communities from EDC and sputum samples of patients according to type 2 (T2)-asthma endotypes.

          Results

          Compared to patients with T2-low SA, patients with T2-high SA exhibited an increase in bacterial alpha-diversity and a decrease in fungal alpha-diversity of their indoor microbial floras, the latter being significantly correlated with FeNO levels. The beta-diversity of the EDC mycobiome significantly clustered according to T2 endotypes. Moreover, the proportion of fungal taxa in common between sputum and EDC samples was significantly higher when patients exhibited acute exacerbation.

          Conclusion

          These results illustrated, for the first time, a potential association between the indoor mycobiome and clinical features of SA patients, which should renew interest in deciphering the interactions between indoor environment, fungi, and host in asthma.

          Graphical abstract

          Abstract

          Capsule summary. This study is the first to date that investigates both the endogenous and the exogenous mycobiomes and microbiomes of asthmatic patients and reveals associations between indoor microbial communities, exacerbation, and T2 of severe asthma.

          Related collections

          Author and article information

          Journal
          J Allergy Clin Immunol
          J. Allergy Clin. Immunol
          The Journal of Allergy and Clinical Immunology
          Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.
          0091-6749
          1097-6825
          12 September 2020
          12 September 2020
          Affiliations
          [1 ]Univ-Bordeaux, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, Département de Pharmacologie, CIC 1401, F-33000 Bordeaux, France
          [2 ]INSERM, Centre de Recherche Cardio-thoracique de Bordeaux, U1045, CIC 1401, F-33000 Bordeaux, France
          [3 ]GenoScreen, Research and Development, Microbiota team, Lille, France
          [4 ]CHU de Bordeaux, Laboratoire de Parasitologie, mycologie, Service d’exploration fonctionnelle respiratoire, Service de pharmacologie, CIC 1401, F-33604 Pessac, France
          Author notes
          []Corresponding Author. Laurence DELHAES, Centre de Recherche Cardio Thoracique de Bordeaux - Inserm U1045, Plateforme Technologique d'Innovation Biomédicale (PTIB), Hôpital Xavier Arnozan, Avenue du Haut Lévêque, 33604 Pessac Cedex, France, Tel: (+33) 05 47 30 27 50; Fax: (+33) 05 57 62 31 73
          Article
          S0091-6749(20)31248-3
          10.1016/j.jaci.2020.08.035
          7486598
          32926879
          31c6e57e-b012-4631-a06c-1bf3a91b5184
          © 2020 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.

          Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

          History
          : 31 January 2020
          : 24 August 2020
          : 26 August 2020
          Categories
          Article

          Immunology
          indoor environment,mycobiome,microbiome,severe asthma,feno,type 2 asthma,bmi, body mass index,bal, bronchoalveolar lavage,cobra, cohort of bronchial obstruction and asthma,edc, electrostatic dust collector,ers, european respiratory society,exa, exacerbation of asthma,feno, fraction of exhaled nitric oxide,ics, inhaled corticosteroid,il, interleukin,its2, internal transcribed spacer 2,laba, long acting beta2 agonist,lda, linear discriminant analysis,lama, long acting muscarinic antagonist,ngs, next generation sequencing,ocs, oral corticosteroid,otu, operational taxonomic unit,pcoa, principal coordinates analysis,permanova, permutational multivariate analysis of variance,qpcr, quantitative polymerase chain reaction,sa, severe asthma,stb, stable state,t2, type 2,vrc, voriconazole,v3-v4, variable 3-variable 4 of the 16s rrna encoding gene

          Comments

          Comment on this article